BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence

Phase 3positiveVOXZOGOPositive

AI Analysis

Summary

BioMarin announced positive Phase 3 results for VOXZOGO (vosoritide) in hypochondroplasia, with findings published in NEJM Evidence. This represents a significant clinical milestone for the company's rare bone disease treatment.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Phase 3 study results published in NEJM Evidence

Importance:7/10

Sentiment:

0.85

Phase 3positive resultspublicationNEJM Evidencerare disease

Related Companies

$BMRN

Read the original article

Published by yahoo_finance on September 9, 2026 1:05 PM

Read Original